What is RegenKit® Extracell®BMC ?


  • The Flexible & Reproducible Bone Marrow Concentrate System
  • Class IIb CE certified Medical Devices
Bone marrow aspirate vol per tube
Bone marrow aspirate vol per tube

4 to 10 ml

MNC recovery
MNC recovery

> 70%

MSC recovery
MSC recovery

> 80%

CFU -F recovery per ml of BMA from the ILIAC CREST
CFU -F recovery per ml of BMA from the ILIAC CREST

– 1000

RegenTHT Tube Properties 1

Bone Marrow Concentrate preparation with RegenKit® Extracell® BMC

Bone marrow concentrate (bmc) is an autologous cell concentrate from bone marrow aspirate.
Bone marrow is a liquid tissue rich in a heterogeneous population of mature cells and multipotent stem cells.
Among them, the mesenchymal stromal cells (MSC) are the musculoskeletal tissue precursor cells.

RegenKit® Extracell® BMC kits are specifically designed for the effective processing of bone marrow aspirate (BMA) by a short centrifugation in RegenTHT tubes. These tubes contain a biologically inert separating gel with a specific density that physically separates the plasma and the mononuclear cell (MNC) fraction, which contains the MSC, from the other bone marrow cellular elements.

More than 80% of the MSC are recovered in the resulting cell concentrate1. In vitro, these cells give rise to fibroblast colony-forming units (CFU-F) capable of undergoing osteogenesis, chondrogenesis and adipogenesis when cultured in their respective specific induction medium1.


Example of a procedure: Bone marrow was processed with the four tubes of the RegenKit® Extracell® BMC.
The resulting BMC will be combined with RegenPRP and ATS prepared from the venous blood of the patients with the tubes from the RegenKit Surgery.

Our products

Filter by:
Regenkit A-PRP
ArthroVisc HA

Clinical evidence in orthopedic surgery

BMC prepared with RegenKit® Extracell® from a small volume of bone marrow aspirate (max 40 ml) have been used successfully for complex bone healing problems such as:

  • Nonunion (Pseudarthrosis)2-3
  • Osteonecrosis (Avascular necrosis of the hip)4-5
  • Bone cysts and large bone loss (after bone tumor removal or trauma)6-8

Complete healing was obtained for around 80% of the lesions1-7

BMC are used alone3, 8, or in combination with bone grafts or synthetic osteoconductive scaffolds4-8.

BMC can also be combined with platelet-rich plasma (RegenPRP) and autologous thrombin serum (ATS) prepared with RegenKit® Surgery to obtain a gel.

Bone substitute or morselized allograft can also be added to this combination to make a bone putty 9.

Intensed use of the device

Preparation of autologous bone marrow cell concentrate
Preparation of Autologous Platelet Rich Plasma & other plasma-derived products


RegenKit® Extracell® BMC

1 Trocar
4 RegenTHT tubes
2 Transfer devices
4 Transfer needles
1 x 80 mm transfer cannula
Self-adhesive discs


RegenKit® Extracell® BMC 2

1 Trocar
2 RegenTHT tubes
2 Transfer devices
2 Transfer needles
1 x 80 mm transfer cannula
Self-adhesive discs


RegenKit® Surgery

1 Safety–LokTM Butterfly needle
1 Collection holder
2 RegenTHT tubes
1 RegenATS tube
1 x 1 ml Luer-LokTM syringe
1 x 5 ml Luer-LokTM syringe
1 Transfer device
2 Transfer needles
2 x 80 mm transfer cannulas
Self-adhesive discs


RegenSpray Applicator

RegenSpray Applicator
1 x 10 ml Luer-LokTM syringe
1 Nozzle for spray application
1 Double piston stopper
1 Applicator syringe holder
1 x 3 ml Luer-LokTM syringe
1 3:10 ratio adapter
1 Luer-lock connector (FM)
1 x 80 mm transfer cannula
1 Transfer needle

Class IIb CE certified Medical Devices. Regen Lab SA is an ISO13485 :2016 and MDSAP certified medical device manufacturer

Warnings and precautions

This kit is intended only for bone reconstruction, orthopedic and traumatological surgeries.

A strict aseptic technique must be followed during bone marrow aspirate. Use proper safety precautions to avoid contact with patient blood or cross-contamination. Use proper safety precautions to guard against needles or broken tubes. Do not use sterile component of this kit if package is opened or damaged. Do not use components of this kit if they are broken or present a defect. Do not use the tube if it lost vacuum. Do not use the sodium citrate solution or other tube components alone. Store between 5ºC and 30ºC; bring kit to ambient temperature before using the tubes. Do not re-sterilise, do not use after the expiry date. Single use device, do not reuse any part of the kit. Reuse may lead to infection or other illness / injury. Transfer needle must be used to transfer liquids only and should not be used for injection. The preparation of the bone marrow concentrate must be performed by a physician trained on the equipment and procedure, or under the supervision of the physician. The treatment with bone marrow concentrate must be performed by a qualified physician. Do not inject bone marrow cell concentrate intravascularly. The patient must be informed of the general risks associated with the treatment and of the possible adverse effects. The safety and effectiveness of combination of bone marrow cell concentrate with other therapies should be assessed by the physician. The safety and effectiveness have not been evaluated in children and in pregnant or lactating women.

The bone marrow cell concentrate must be prepared from fresh blood and must be used within four hours (extemporaneous use only). All tubes and components of the kit are to be entirely discarded by elimination method after each use to avoid potential contamination with blood products. Use a 45° fixed angle rotor centrifuge or a horizontal head swinging bucket centrifuge (ex. RegenPRP Centri provided by Regen Lab). Follow the manufacturer’s instructions when using the centrifuge. Tubes should be centrifuged, as recommended in the instructions for use, at a relative centrifugation force (RCF) of 1500 g. Excessive RCF (over 2200 g) may lead to tube breakage resulting in blood exposure, and possible injury. RCF below 1500 g may lead to incorrect blood separation and red blood cell contamination of bone marrow cell concentrate. Centrifuge carriers and inserts size should be adapted to the tubes. Use of carriers too large or too small may result in breakage of the tubes. Caution should be taken to ensure that tubes are properly seated in the centrifuge carriers. Tubes must be balanced in the centrifuge.

Possible adverse effects

Haemorrhage, hematoma, delayed wound healing. Early or late operative infection. Persistent pain, seromas. Allergic reaction to anaesthesia.

Patented by Regen Lab SA
Platelet Rich Plasma

U.S. patent US8529957
European patent EP2073862B
Swiss patent CH696752

All our Patent


  1. Barry, F., A Report on The Phenotypic Characterisation of Mesenchymal Stem Cells isolated from Human Bone Marrow Using the RegenTHT, A-CP and Regen BCT Blood
    Separation Systems. 2015, The Regenerative Medicine Institute (REMEDI), National University of Ireland Galway.
  2. caglione, M., et al., Long bone nonunions treated with autologous concentrated bone marrow-derived cells combined with dried bone allograft.
    Musculoskelet Surg, 2014. 98(2): p. 101-6.
  3. Toro, G., et al., Surgical treatment of neglected hip fracture in children with cerebral palsy: case report and review of the literature.
    Clin Cases Miner Bone Metab, 2017. 14(3): p. 317-23.
  4. Civinini, R., et al., The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head.
    Int Orthop, 2012. 36(8): p. 1583-8.
  5. De Biase, P., et al., Regenerative Medicine In The Treatment Of Osteonecrosis Of The Hip: A Comparative Clinical Study On The Use Of Autologous Cell Concentrates In The
    Presence Or Absence Of BMP, in EFORT congress. 2016: Geneva. p. #1343 – Free Papers.
  6. De Biase, P., et al., Scaffolds combined with stem cells and growth factors in healing of pseudotumoral lesions of bone. Int J Immunopathol Pharmacol, 2011. 24(1 Suppl 2): p. 11-5.
  7. De Biase, P., et al., The “in-Vivo Cell Factory” Concept As An Alternative To Traditional Tissue Engineering In The Repair Of Large Cavitary Bone Defects., in EFORT congress.
    2016: Geneva. p. #1344 – Free Papers.
  8. Andreani, L., et al., Bone Marrow Concentrate in the Treatment of Aneurysmal Bone Cysts: A Case Series Study. Stem Cells Int, 2020. 2020: 8898145.
  9. Bertolai, R., et al., Bone graft and mesenchimal stem cells: clinical observations and histological analysis. Clin Cases Miner Bone Metab, 2015. 12(2): p. 183-7.

Contact Regenlab

Now is the time to change your life. Browse resources and get
connected to treatment that is right for them.

For more information on our products, please contact us by clicking on the button below:


Our Regional offices are
located in

  • New York (USA)
  • Montréal (Canada)
  • Venice (Italy)
  • Munich (Germany)
  • Paris (France)
  • Dubai (U.A.E.)
  • Beijing (China)
  • Istanbul (Turkey)